EULAR 2018 - Day 1 Report
Opening to a record attendance, EULAR 2018 started today with opening ceremonies that included the induction of honorary EULAR members:
Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)
Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.
The RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
The RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis and modifiable behaviors that influence outcomes.
The RheumNow Week in Review - Nonadherence and Astronomic Costs (5.11.18)
Dr. Jack Cush reviews highlights, news and journal articles from the past week on RheumNow.com.
The RheumNow Week in Review – Why Comorbidity is Like the Weather (5.3.18)
Dr. Jack Cush discusses the news and journal articles from the past week on RheumNow.com.
The RheumNow Week in Review – FDA Showdown for Baricitinib (4.27.18)
Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.
The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.
RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory SLE.
Uveitis in JIA: Screen All, Treat Early
A European group of experts has formulated consensus-based recommendations for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, focusing on screening, monitoring, and treatment of this potentially devastating extra-articular manifestation of JIA.
Rituximab May Halt ILD in Antisynthetase Syndrome Myositis
A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most.
The RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Social
ACR has released 2 free powerpoint slide decks featuring select RA and SLE abstracts from #ACR20 (a 3rd late-breaking slide deck is yet to come!). Download here>> https://t.co/CiNH0xfs7J
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Racial Disparities - Stroke, Heart Attacks Risks Higher in SLE: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #0433 presented Friday at #ACR20 annual meeting.
https://t.co/Jx8hiPcNKA https://t.co/MvUj41KiuQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years ago
Watch Dr. Janet Pope review abstracts #1198 and #1473 on lifestyle and risk of RA, lupus presented at the #ACR20 annual meeting.
https://t.co/SAffgj4i5l https://t.co/VCpMbN3zmg
Links:
Dr. John Cush @RheumNow ( View Tweet )
5 years 1 month ago
Smartphone T2T management of RA & SLE is possible. With over 127,316 DAS28 & 42,593 SLEDAI assessments over 2 yrs. T2T was lowest in spring for both, correlating w/ holidays in China. #ACR20 Abstr#1018 https://t.co/bGJtSTDqzo https://t.co/34za6kokOp
Dr. John Cush @RheumNow ( View Tweet )
5 years 1 month ago
Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis
-Compared to rituximab, has more B-cell depletion in tissue and #SLE patients
-Meaningful benefits over SOC alone on renal response through week 104.
-Phase 3 REGENCY pending.
#ACR20
#ACRambassador
#Rheumatology https://t.co/aPi1yueAiV
Mohammad A. Ursani MD, RhMSUS @DrMAUrsani ( View Tweet )
5 years 1 month ago
@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT
Eric Dein @ejdein1 ( View Tweet )
5 years 1 month ago
Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed
alexa meara @lexmeara ( View Tweet )
5 years 1 month ago
Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis.
How/when do you use IVIG for tx of DM?
@RheumNow #ACR20
Robert B Chao, MD @doctorRBC ( View Tweet )
5 years 1 month ago
ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph 3 trial. @RheumNow #ACR20 abs0995 #ACRbest https://t.co/aJyASaAMlJ
sheila @RHEUMarampa ( View Tweet )
5 years 1 month ago
#HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE:
- 132 patients, 108 on HCQ
- Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways
- HCQ may improve vascular health in SLE
Abs#0870 #ACR20 @RheumNow
https://t.co/ST9n2HGyhM
Mrinalini Dey @DrMiniDey ( View Tweet )
5 years 1 month ago
